Literature DB >> 14888691

Multiple myeloma. IV. Abnormal serum components and Bence Jones protein.

R W RUNDLES, G R COOPER, R W WILLETT.   

Abstract

Entities:  

Keywords:  MYELOMA, PLASMA CELL/blood in; PROTEINS/metabolism

Mesh:

Substances:

Year:  1951        PMID: 14888691      PMCID: PMC436355          DOI: 10.1172/JCI102533

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


× No keyword cloud information.
  11 in total

1.  The serum proteins in multiple myelomatosis.

Authors:  R A Kekwick
Journal:  Biochem J       Date:  1940-09       Impact factor: 3.857

2.  Immunological differences of crystalline Bence-Jones proteins.

Authors:  L Hektoen; W H Welker
Journal:  Biochem J       Date:  1940-04       Impact factor: 3.857

3.  The behaviour of pathological sera in the ultracentrifuge.

Authors:  A S McFarlane
Journal:  Biochem J       Date:  1935-05       Impact factor: 3.857

4.  BENCE-JONES PROTEINEMIA IN MULTIPLE MYELOMA.

Authors:  D H Moore; E A Kabat; A B Gutman
Journal:  J Clin Invest       Date:  1943-01       Impact factor: 14.808

5.  A VISCOUS PROTEIN OBTAINED IN LARGE AMOUNT FROM THE SERUM OF A PATIENT WITH MULTIPLE MYELOMA.

Authors:  S Shapiro; V Ross; D H Moore
Journal:  J Clin Invest       Date:  1943-03       Impact factor: 14.808

6.  FRACTIONATION OF SERUM PROTEINS IN HYPERPROTEINEMIA, WITH SPECIAL REFERENCE TO MULTIPLE MYELOMA.

Authors:  A B Gutman; D H Moore; E B Gutman; V McClellan; E A Kabat
Journal:  J Clin Invest       Date:  1941-11       Impact factor: 14.808

7.  Immunological investigations in ten cases of plasmacytoma.

Authors:  F H WUHRMANN; C WUNDERLY; A HASSIG
Journal:  Br J Exp Pathol       Date:  1950-08

8.  Multiple myeloma. III. Effect of urethane therapy on plasma cell growth, abnormal serum protein components and Bence Jones proteinuria.

Authors:  R W RUNDLES; M L DILLON; E S DILLON
Journal:  J Clin Invest       Date:  1950-09       Impact factor: 14.808

9.  A study of renal function in patients with multiple myeloma.

Authors:  J B ARMSTRONG
Journal:  Am J Med Sci       Date:  1950-05       Impact factor: 2.378

10.  Cryoglobulinemia; report of two cases with discussion of clinical manifestations, incidence and significance.

Authors:  D P BARR; G G READER; C H WHEELER
Journal:  Ann Intern Med       Date:  1950-01       Impact factor: 25.391

View more
  18 in total

1.  The occurrence of post-gamma protein in urine: a new protein abnormality.

Authors:  E A BUTLER; F V FLYNN
Journal:  J Clin Pathol       Date:  1961-03       Impact factor: 3.411

2.  [INCIDENCE AND CLINICAL SIGNIFICANCE OF PARAPROTEINEMIA].

Authors:  H H MAERKI; F WUHRMANN
Journal:  Klin Wochenschr       Date:  1965-01-15

3.  [New viewpoints in the evaluation of proteinuria in plasmocytoma. II].

Authors:  H WEICKER; K HUHNSTOCK
Journal:  Klin Wochenschr       Date:  1962-01-01

4.  Further studies of the gamma-related proteins of normal urine.

Authors:  G T STEVENSON
Journal:  J Clin Invest       Date:  1962-05       Impact factor: 14.808

5.  [On the urethane gel reaction of paraproteins].

Authors:  K HUHNSTOCK; A DISTLER
Journal:  Klin Wochenschr       Date:  1963-03-01

6.  [Paraproteinurias with negative results of the albustix test].

Authors:  K HUHNSTOCK
Journal:  Klin Wochenschr       Date:  1962-10-01

7.  [New viewpoints in the analysis of proteinuria in plasmocytoma. I].

Authors:  H WEICKER; K HUHNSTOCK
Journal:  Klin Wochenschr       Date:  1961-05-01

8.  Detection in normal urine of protein resembling Bence Jones protein.

Authors:  G T STEVENSON
Journal:  J Clin Invest       Date:  1960-07       Impact factor: 14.808

9.  Multiple myelomatosis: a review based on 68 patients.

Authors:  J R MARTIN; L JOHNSON
Journal:  Can Med Assoc J       Date:  1957-04-15       Impact factor: 8.262

10.  Incorporation of N15-L-aspartic acid into the abnormal serum and urine proteins of multiple myeloma; studies of the inter-relationship of these proteins.

Authors:  E F OSSERMAN; A GRAFF; M MARSHALL; D LAWLOR; S GRAFF
Journal:  J Clin Invest       Date:  1957-02       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.